CD300LD and neoplasm: In tumor‐bearing mice, both tasquinimod treatment and CD300ld gene knockout inhibited PMN‐MDSC migration and reduced immunosuppressive effects, suggesting that drugs targeting CD300ld could exhibit comparable antitumor efficacy to those targeting S100A8/S100A9 [54].